Acute Bronchitis Treatment Market

Global Acute Bronchitis Treatment Market Size, Share And Trend Analysis Report By Product Type (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Mucolytics), By End-User (Hospital Pharmacy, Retail Pharmacies, Online Pharmacies) Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025284 | Category : Pharmaceuticals | Delivery Format: /

The global acute bronchitis treatment market is expected to grow at a significant CAGR during the forecast period (2021-2027). Acute bronchitis, sometimes known as a chest cold, is caused by a cough and a cold. It normally goes away in a week to ten days without leaving any lasting consequences, though the cough may linger for a few weeks. In the US, an estimated 5% of the general population suffers from acute bronchitis each year. Toxic chemicals and pollutants, such as ammonia and sulphur dioxide, increase the risk of chronic bronchitis. People who suffer from allergies to pollens and dust frequently develop acute bronchitis. 

A huge patient pool is one of the primary factors driving the global acute bronchitis treatment market growth. In addition, harmful habits such as smoking, as well as rising levels of chemical pollutants, are important drivers driving the market's growth. Furthermore, a sedentary lifestyle and the availability of bronchitis treatment are propelling the global acute bronchitis treatment market growth. On the other side, several factors stifle market expansion, such as patent expiration. The growing use of acute bronchitis treatment in hospitals, retail pharmacies, online pharmacies, and other industries is propelling the global acute bronchitis treatment market. 

Bronchodilators are medications that open the airway channels and enlarge the windpipe, making it easier to breathe for people with lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD). Bronchodilators are the first-line treatment for bronchitis as they clear the airway obstruction, which is necessary for chronic bronchitis to ease the patient’s breathing. The market segment is growing due to main factors such as the rising incidence of respiratory disorders and the rising prevalence of smoking. As a result, bronchodilators are in more demand as the frequency of respiratory disorders rises.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: AstraZeneca, Boehringer Ingelheim International, GlaxoSmithKline, Novartis AG, Melinta Therapeutics among others. 

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Acute Bronchitis Treatment Market by Segment

By Product Type 

Antibiotics

Anti-inflammatory Drugs

Bronchodilator

Mucolytics 

By End-User 

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies 

Global Acute Bronchitis Treatment Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World